Research programme - 5T4 monoclonal antibody conjugates - Oxford BioMedica/Pfizer

Drug Profile

Research programme - 5T4 monoclonal antibody conjugates - Oxford BioMedica/Pfizer

Alternative Names: 5T4 MAb-toxin; Anti-5T4 antibody; CME-548; OBA1-H8

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford BioMedica
  • Developer Pfizer
  • Class Aminoglycosides; Antineoplastics; Drug conjugates; Enediynes; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Membrane glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 06 Sep 2013 Preclinical development in Cancer is ongoing in USA
  • 04 May 2011 Oxford BioMedica broadens 5T4 antibody collaboration with Pfizer; Pfizer granted non-exclusive rights for the diagnostic use of 5T4 antibodies in an amendment to an existing licensing agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top